TOMM40 '523 Genotype Distinguishes Patterns of Cognitive Improvement for Executive Function in APOEɛ3 Homozygotes.
APOE
Alzheimer’s disease
TOMM40
cognition
executive function
longitudinal
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
23
10
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
ppublish
Résumé
TOMM40 '523 has been associated with cognitive performance and risk for developing Alzheimer's disease independent of the effect of APOE genotype. Few studies have considered the longitudinal effect of this genotype on change in cognition over time. Our objective was to evaluate the relationship between TOMM40 genotype status and change in cognitive performance in the TOMMORROW study, which was designed to prospectively evaluate an algorithm that includes TOMM40 '523 for genetic risk for conversion to mild cognitive impairment. We used latent growth curve models to estimate the effect of TOMM40 allele carrier (short, very long) status on the intercept and slope of change in cognitive performance in four broad cognitive domains (attention, memory, executive function, and language) and a combined overall cognitive score over 30 months. TOMM40 very long allele carriers had significantly lower baseline performance for the combined overall cognitive function score (B = -0.088, p = 0.034) and for the executive function domain score (B = -0.143, p = 0.013). Slopes for TOMM40 very long carriers had significantly greater increases over time for the executive function domain score only. In sensitivity analyses, the results for executive function were observed in participants who remained clinically stable, but not in those who progressed clinically over the study duration. Our results add to the growing body of evidence that TOMM40, in the absence of APOEɛ4, may contribute to cognitive changes with aging and dementia and support the view that mitochondrial function is an important contributor to Alzheimer's disease risk.
Sections du résumé
BACKGROUND
TOMM40 '523 has been associated with cognitive performance and risk for developing Alzheimer's disease independent of the effect of APOE genotype. Few studies have considered the longitudinal effect of this genotype on change in cognition over time.
OBJECTIVE
Our objective was to evaluate the relationship between TOMM40 genotype status and change in cognitive performance in the TOMMORROW study, which was designed to prospectively evaluate an algorithm that includes TOMM40 '523 for genetic risk for conversion to mild cognitive impairment.
METHODS
We used latent growth curve models to estimate the effect of TOMM40 allele carrier (short, very long) status on the intercept and slope of change in cognitive performance in four broad cognitive domains (attention, memory, executive function, and language) and a combined overall cognitive score over 30 months.
RESULTS
TOMM40 very long allele carriers had significantly lower baseline performance for the combined overall cognitive function score (B = -0.088, p = 0.034) and for the executive function domain score (B = -0.143, p = 0.013). Slopes for TOMM40 very long carriers had significantly greater increases over time for the executive function domain score only. In sensitivity analyses, the results for executive function were observed in participants who remained clinically stable, but not in those who progressed clinically over the study duration.
CONCLUSIONS
Our results add to the growing body of evidence that TOMM40, in the absence of APOEɛ4, may contribute to cognitive changes with aging and dementia and support the view that mitochondrial function is an important contributor to Alzheimer's disease risk.
Identifiants
pubmed: 37718796
pii: JAD230066
doi: 10.3233/JAD-230066
pmc: PMC10578241
doi:
Substances chimiques
Apolipoproteins E
0
TOMM40 protein, human
0
Mitochondrial Precursor Protein Import Complex Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1697-1707Références
Alzheimers Dement (N Y). 2019 Oct 28;5:661-670
pubmed: 31720367
Neuron. 2004 Sep 30;44(1):195-208
pubmed: 15450170
Neurology. 2017 Feb 14;88(7):661-668
pubmed: 28108637
Cortex. 2018 Jul;104:103-123
pubmed: 29800787
Cereb Cortex. 2007 Aug;17(8):1934-47
pubmed: 17077159
J Hum Genet. 2012 Jan;57(1):18-25
pubmed: 22089642
Alzheimers Dement (N Y). 2018 Jul 14;4:314-323
pubmed: 30094331
Pharmacogenomics J. 2010 Oct;10(5):375-84
pubmed: 20029386
Neurobiol Aging. 2014 Jun;35(6):1513.e25-33
pubmed: 24508314
Philos Trans R Soc Lond B Biol Sci. 2020 Nov 9;375(1811):20190618
pubmed: 32951543
Alzheimers Dement. 2017 Nov;13(11):1217-1225
pubmed: 28549947
Alzheimers Dement. 2011 Jul;7(4):456-65
pubmed: 21784354
Neurol Genet. 2020 Mar 03;6(2):e404
pubmed: 32337333
J Prev Alzheimers Dis. 2022;9(4):625-634
pubmed: 36281666
Antioxid Redox Signal. 2012 Jun 15;16(12):1434-55
pubmed: 21902597
Science. 2001 Feb 16;291(5507):1232-49
pubmed: 11233447
J Alzheimers Dis. 2019;70(4):1059-1068
pubmed: 31322569
Curr Dir Psychol Sci. 2015 Jul 1;24(4):304-312
pubmed: 26556960
Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2973-2986
pubmed: 28768149
Alzheimers Dement. 2012 Nov;8(6):490-5
pubmed: 23102119
Alzheimers Dement. 2021 Aug;17(8):1287-1296
pubmed: 33580752
Am J Public Health. 2013 Oct;103 Suppl 1:S152-66
pubmed: 23927501
Alzheimers Dement. 2018 May;14(5):692-698
pubmed: 29524426
Alzheimers Dement. 2014 Sep;10(5):541-51
pubmed: 24439168
Neurobiol Aging. 2016 Mar;39:217.e1-7
pubmed: 26742953
Front Hum Neurosci. 2013 May 22;7:198
pubmed: 23734114
Neurobiol Aging. 2015 Jun;36(6):2024-33
pubmed: 25862420
Biochim Biophys Acta. 2014 Aug;1842(8):1219-31
pubmed: 24071439
Alzheimers Dement. 2017 Jul;13(7):739-748
pubmed: 28183529
PLoS One. 2017 Aug 11;12(8):e0182448
pubmed: 28800603